AI in Medical Writing Market Report 2026

The artificial intelligence (AI) in medical writing market size has grown rapidly in recent years. It will grow from $1.05 billion in 2025 to $1.21 billion in 2026 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to increasing volume of clinical trials, rising complexity of regulatory documentation, shortage of skilled medical writers, growth in pharmaceutical r&d activities, increasing need for faster medical documentation.

The artificial intelligence (AI) in medical writing market size is expected to see rapid growth in the next few years. It will grow to $1.99 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to increasing adoption of generative AI models, rising demand for real-time regulatory updates, expansion of AI-assisted pharmacovigilance, growing focus on multilingual medical content, increasing integration with clinical data platforms. Major trends in the forecast period include increasing adoption of AI-assisted clinical documentation, rising use of automated literature review tools, growing integration of AI in regulatory submissions, expansion of content modularization platforms, enhanced focus on data accuracy and compliance.

The increasing demand for new pharmaceutical drugs and therapies is expected to drive growth in the artificial intelligence (AI) in medical writing market going forward. This demand is fueled by the ongoing need to address unmet medical needs, treat emerging diseases, combat drug resistance, and improve patient outcomes through innovative and effective treatments. AI in medical writing within the pharmaceutical and drug development sectors enhances efficiency, accuracy, and innovation, supporting the creation of safer and more effective therapies for various medical conditions. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. These newly approved treatments included seven cancer drugs and three for other diseases and conditions. Therefore, the growing demand for new pharmaceutical drugs and therapies is driving the AI in medical writing market.

Leading companies in the AI medical writing sector are focusing on integrating advanced features, such as AI-powered drafting, to optimize efficiency and precision in document creation and management for regulatory submissions and medical communications. AI-powered drafting leverages machine learning and natural language processing algorithms to automate initial document drafts or outlines, significantly streamlining content creation tasks. For instance, TrialAssure, a US-based pharmaceutical technology provider, launched TrialAssure LINK AI 2 in June 2024. This upgraded platform enables pharmaceutical and biotechnology firms, clinical research organizations, and service providers to efficiently generate a wide range of regulatory and medical writing documents using AI. The solution automates document creation from initial drafting through to final approval stages, enhancing the overall authoring process.

In March 2024, Indegene Limited, a US-based company specializing in life sciences commercialization, acquired Trilogy Writing & Consulting GmbH for an undisclosed sum. This acquisition bolstered Indegene’s capabilities in clinical and regulatory writing for global market authorization applications. Additionally, the acquisition deepened Indegene's commitment to content automation, particularly leveraging generative AI, to enhance outcomes for clients in clinical, regulatory writing, and related services. Trilogy Writing & Consulting GmbH, headquartered in Germany, provides medical writing and regulatory documentation services utilizing AI-based tools.

Major companies operating in the artificial intelligence (AI) in medical writing market are IQVIA Holdings Inc., ICON PLC, Parexel International Corporation, Syneos Health, Veeva Systems, Certara Inc., Indegene, Freyr Solutions, Trilogy Writing & Consulting GmbH, Yseop S.A.S., TrialAssure, Multiplier AI, Abridge, Cactus Communications, MMS Holdings Inc., Averbis GmbH, Narrativa Inc., DeepCura AI, DezzAI Inc, Turacoz Healthcare Solution, EMTEX Life Sciences, Jasper AI Inc., GenInvo Technologies Pvt. Ltd.

North America was the largest region in the artificial intelligence (AI) in medical writing market in 2025. The regions covered in the artificial intelligence (AI) in medical writing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) in medical writing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the AI in medical writing market by increasing costs associated with imported cloud infrastructure components, data processing hardware, and specialized AI development tools used by solution providers. North America and Europe are most affected due to dependence on cross-border cloud services and AI platforms, while Asia-Pacific faces cost pressures related to outsourced AI development resources. These tariffs are increasing operational costs for vendors and slowing adoption among smaller pharmaceutical firms. However, they are also encouraging regional data center investments, localized AI model development, and increased adoption of cost-efficient cloud-native medical writing solutions.

The artificial intelligence (AI) in medical writing market research report is one of a series of new reports that provides artificial intelligence (AI) in medical writing market statistics, including artificial intelligence (AI) in medical writing industry global market size, regional shares, competitors with a artificial intelligence (AI) in medical writing market share, detailed artificial intelligence (AI) in medical writing market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in medical writing industry. This artificial intelligence (AI) in medical writing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence (AI) in medical writing involves the use of intelligent technologies to streamline and improve the creation of medical documents, such as research papers, clinical trial reports, regulatory submissions, patient information leaflets, and other healthcare-related content. AI enhances efficiency, accuracy, and accessibility in these tasks, thereby contributing to advancements in medical research and healthcare delivery.

The primary categories of AI in medical writing encompass clinical writing, typewriting, scientific writing, and various other applications. Clinical writing focuses on producing documents related to clinical trials and medical studies, including protocols, study reports, and informed consent forms that detail the procedures and outcomes of clinical research. AI applications extend to regulatory documentation, automated literature reviews, language translation, pharmacovigilance, and content modularization for end users in sectors such as medical devices, pharmaceuticals, biotechnology, and related fields.

The artificial intelligence (AI) in medical writing market consists of revenues earned by entities by providing services such as automated content generation, proofreading and editing, regulatory compliance, and literature review. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) in medical writing market also include sales of high-performance computers, graphics processing units, and storage devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.